Nanoparticles are being investigated for numerous medical applications and are showing potential as an emerging class of carriers for drug delivery. Investigations on how the physicochemical properties (e.g., size, surface charge, shape, and density of targeting ligands) of nanoparticles enable their ability to overcome biological barriers and reach designated cellular destinations in sufficient amounts to elicit biological efficacy are of interest. Despite proven success in nanoparticle accumulation at cellular locations and occurrence of downstream therapeutic effects (e.g., target gene inhibition) in a selected few organs such as tumor and liver, reports on effective delivery of engineered nanoparticles to other organs still remain scarce. Here, we show that nanoparticles of ∼75 ± 25-nm diameters target the mesangium of the kidney. These data show the effects of particle diameter on targeting the mesangium of the kidney. Because many diseases originate from this area of the kidney, our findings establish design criteria for constructing nanoparticle-based therapeutics for targeting diseases that involve the mesangium of the kidney.
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gold nanoparticles | kidney targeting | mesangial cells | particle size C onstructing nanoparticles for drug delivery requires knowledge in colloidal science and biology, where biological constraints generally dictate the design of nanoparticle therapeutics and imaging agents (1) (2) (3) (4) . A celebrated design criterion is the notion of renal clearance (5, 6) . That is, nanoparticles will experience rapid clearance by the kidney if they are smaller than ∼10 nm in diameter. Such clearance originates from the innate function of the kidney as a blood filter.
The structural and functional unit of the kidney, the nephron, consists of the renal corpuscle and tubule system. The renal corpuscle contains a tuft of blood capillaries and support tissue (the mesangium) (Fig. S1 ) called the glomerulus. A fraction of blood plasma entering the glomerulus will pass through the glomerular filtration apparatus to produce an ultrafiltrate, which will be collected by the tubule system and ultimately, processed into urine. The first component is the glomerular endothelium, with pores that have been reported to be in the range of 80-100 nm in diameter (7) . Next, the glomerular basement membrane (GBM), a 300-to 350-nm-thick basal lamina rich in heparan sulfate (8) and charged proteoglycans with an average pore size of 3 nm (9), filters small molecules by size and charge. Behind the GBM lies podocytes, cells with interdigitating foot processes that form filtration slits that are 32 nm wide (10) . The glomerular filtration apparatus, taken in its entirety, possesses an effective size cutoff of 10 nm, and it is responsible for the rapid renal clearance of small nanoparticles. Many nanoparticle-based contrasting agents for in vivo imaging were designed to be smaller than this size cutoff (11, 12) . Prolonged residency of nanoparticles in the kidney has been shown to induce toxicity in the form of cell shrinkage because of excessive nanoparticle uptake by renal cells (13, 14) . Closer examination of the renal corpuscle reveals the existence of another intriguing size cutoff that would affect the distribution pattern. Within the renal corpuscle, in the absence of GBM and podocytes, the sole dividing barrier between the mesangium (mesangial cells and extracellular matrix) and the glomerulus is the fenestrated endothelium. Submicronsized nanoparticles may feasibly diffuse and accumulate indefinitely in the mesangium after they depart from the glomerulus through these pores. Here, we illustrate the size-dependent delivery of PEGylated gold nanoparticles to the kidney mesangium.
Results and Discussion
Assembly of Au x -PEG y Nanoparticles. Gold-based nanoparticles (AuNPs) were used here for the following reasons. They are compatible with multiple imaging methods. As rigid and nondecomposable objects, submicron-sized AuNPs larger than ∼10 nm cannot escape the kidney by renal clearance. Unmodified gold nanoparticles of different sizes have ζ-potentials ranging from −19 to −28 mV. The measured ζ-values are consistent with predictions using classical electrokinetic theory (Fig. S2 ), and they suggest that unmodified AuNPs of all sizes share the same surface charge density (σ). Next, to create particles of the same surface charge, we exploit the charge screening effect of PEG. The larger that the gold particles are, the more negative that the surface charge is. Thus, creating a set of nanoparticles with variable size and relatively constant surface charge would require the engraftment of longer PEG chains onto the larger nanoparticles. This concept prompted us to use an assortment of PEGylated Au x -PEG y NPs possessing gold particles of different core diameters (x) and PEGs of different chain lengths (y) ( Table  1 ). The engraftment procedure entailed the use of methoxy-PEG-thiol (mPEG-SH) molecules, whose terminal thiol groups can react with the gold surface through the formation of goldthiol covalent bonds. Careful choice of x and y gave rise to a near-constant ζ (roughly −10 mV) for Au x -PEG y NPs of various final hydrodynamic sizes (Table 1 ). In general, the engraftment of each additional 2,000 molecular weight of PEG onto the gold surface translates to an increase of 5 nm in the hydrodynamic diameter of Au x -PEG y NPs. This approximate linearity between the PEG corona thickness and chain length is consistent with previous predictions for tethered polymer brushes on spherical interfaces without pronounced curvature (15) (Tables  S1 and S2 ). All Au x -PEG y NPs showed stability in salt solution after 24 h, with hydrodynamic sizes in PBS roughly equal to those in water (Table 1 ).
Blood Pharmacokinetics. BALB/c mice (n = 3) received single i.v. injections of each type of Au x -PEG y NP at the same particle concentration. From each mouse, blood was withdrawn through the saphenous vein at various time points to evaluate for gold content using inductively coupled plasma MS (ICP-MS). With extensive surface engraftment of PEG (y ≥ 4,000), all particles manifested extended blood circulation, with a half-life (t 1/2 ) that spans from 7 to 38 h. Particle size and t 1/2 were inversely correlated ( Fig. 1A and Table S3 ). The simultaneous increase in x and y led to reduction in t 1/2 , indicating that size-dependent internal clearance, not colloidal stability conferred by PEGylation, played a dominant role in determining particle blood circulation.
Organ-Level Distribution. Mice were then euthanized 24 h after injection to extract organs for detection of bulk gold content using ICP-MS. For all particle sizes, gold content of the six organs plus the blood samples collected at three time points summed up to ≥70% injected dose (ID), thus constituting a mass balance that accounts for the destinations of most injected Au x -PEG y NPs. Overall, the liver, spleen, and kidney were the main sites of particle accumulation, whereas the lung, pancreas, and heart showed negligible (<0.5% ID) particle retention ( Fig. 1B and Table S4 ). At 24 h after dosing, the liver and spleen both showed a positive correlation between particle size and degree of particle uptake, which is in agreement with previous reports that the degree of particle phagocytosis by Kupffer cells and spleen macrophages is largely size-dependent [the larger the nanoparticles, the greater the uptake in the reticuloendothelial system (RES)] (16). From Fig. 1 , the blood nanoparticle content at 24 h seems to correlate with uptake by the RES (increased uptake by the RES is accompanied by lower content in the blood, leading to shorter circulation half-life). Lastly and most importantly, the kidney revealed an unexpected size-dependent nanoparticle retention pattern; there exists a particle size (Au 50 -PEG 5,000 ) at which renal accumulation is maximal.
Tissue-Level Renal Distribution. To understand the size-dependent accumulation in the kidney, we prepared silver-enhanced kidney sections to reveal the distribution of Au x -PEG y NPs at the tissue level. Gold selectively catalyzes the reduction of silver ions and deposition of metallic silver, making nano-sized objects embedded in kidney sections visible under light microscopy. Within the cortex, most particles resided either near resident phagocytes GTE, glomerular targeting efficiency; HD, hydrodynamic diameter; t 1/2 , blood half-life; x, core diameter of AuNP; y, chain length of grafted PEG; SI, staining index (an arbitrary score that ranks both the intensity and spread of the silver stain, where +++ and 0 are the maximum and minimum values, respectively); ZP, ζ-potential in 1 mM KCl; Ω, kidney bulk particle content. The table presents in vitro data as average ± SD from triplicates of experiments as well as in vivo data as average ± SD from three animals per particle type. within peritubular capillaries, which intertwine the cortical tubules (proximal convoluted tubules and distal convoluted tubules), or inside renal corpuscles.
Particle accumulation at peritubular capillaries did not show clear correlation with size (Fig. S3) . However, particle accumulation inside renal corpuscles reveals a strong function of size (Fig. 2) . The smallest particles (Au 5 -PEG 5,000 ) were virtually undetectable in the renal corpuscles but were found in peritubular capillaries (Fig. S4A) . Au 20 -PEG 5,000 nanoparticles accumulated in the renal corpuscles and rarely accumulated in the peritubular capillaries. Only ∼50% of the renal corpuscles contained Au 20 -PEG 5,000 NPs, and the staining scattered all over the extracellular space (mesangium) outside the mesangial cells. The staining intensity seemed mild (Fig. 2A) . For Au 40 -PEG 4,000 NPs, particle staining within the renal corpuscles became more intense; ∼80% of the renal corpuscles were stained positive for particles, and staining localized closer to mesangial cells (Fig. S4B) .
Similar accumulation patterns were apparent for Au 50 -PEG 5,000 NPs, except that 100% of the renal corpuscles examined under the light microscope were stained positive for particles. Closer inspection of each renal corpuscle revealed that the most intense silver is adjacent to mesangial cells throughout the largest area fraction of the renal corpuscles among all particle sizes (Fig. 2B) . Incidentally, this complete glomerular targeting efficiency (GTE) matches strongly with the maximal bulk particle content in the kidney observed for Au 50 -PEG 5,000 NPs. The GTE for Au 60 -PEG 7,000 NPs was also close to complete (∼90%), and such particles also elicited very intense silver staining near the mesangial cells (Fig. S4C) .
Finally, Au 80 -PEG 10,000 and Au 100 -PEG 20,000 NPs gave a GTE of 60-70%. Because of the catalytic nature of staining, larger Au x -PEG y NPs are expected to produce more silver deposition on their periphery. Although silver staining can confirm the presence of Au x -PEG y NPs, the intensity alone does not provide the quantitation of actual particle content. Thus, besides the absolute magnitude of intensity, the spread of staining (areal fraction covered by silver) within renal corpuscles is also an important measure. We report in Table 1 what we denote as the staining index (SI), an arbitrary measure that accounts for both intensity and spread of staining. For the highest score (i.e., +++), particles (like Au 50 -PEG 5,000 NPs) accumulated in the highest areal fraction of the renal corpuscles and also, accumulated at the highest intensity. Typically, the same particles can achieve a high GTE, meaning that they can be found frequently in different renal corpuscles throughout the cortex. For the lowest score (i.e., 0), particles (like Au 5 -PEG 5,000 NPs) resided in limited areas of the renal corpuscles and usually, resided at undetectable densities. Typically, the same particles can achieve a low GTE, implying their low occurrence in different renal corpuscles throughout the cortex.
For Au 80 -PEG 10,000 NPs, silver staining was found in limited regions of renal corpuscles, despite their intense staining, yielding an SI score of ++. The largest particles, Au 100 -PEG 20,000 NPs, barely occupied a sizeable areal fraction of the renal corpuscles and showed very modest staining, leading to their score of + for the SI. Overall, the SI of the largest nanoparticles (Au 80 -PEG 10,000 and Au 100 -PEG 20,000 NPs) was lower than that of Au 50 -PEG 5,000 NPs. Taken together, Au 80 -PEG 10,000 and Au 100 -PEG 20,000 NPs target 60-70% of the renal corpuscles and within each corpuscle, target a very limited area fraction and moderately intense staining.
The histological data collectively suggest a size-dependent localization of Au x -PEG y NPs within renal corpuscles in the kidney cortex. Because such particles do not have a constant PEG chain length, one may question whether the distribution of nanoparticles in renal corpuscles is PEG-dependent. To address this point, we investigated the tissue-level in vivo distribution of Au 80 -PEG 5,000 NPs (hydrodynamic size = 97.1 ± 1.9 nm; ζ-potential = −16.77 ± 1.14 mV) in renal corpuscles, noting that such particles possess a very similar hydrodynamic size and ζ-potential of Au 60 -PEG 7,000 NPs. Histological analysis reveals accumulation of Au 80 -PEG 5,000 NPs in the renal corpuscles in similar intensity and area as that of Au 60 -PEG 7,000 NPs but not Au 80 -PEG 10,000 NPs, supporting the suggestion that the distribution of nanoparticles in renal corpuscles is size-dependent.
Cellular-Level Renal Distribution. Transmission electron microscopy (TEM) was used to determine the intracellular localization patterns of the nanoparticles residing in the renal cortex. In agreement with the histological data, particles of all sizes were either engulfed by resident phagocytes or remained as isolated entities in circulation inside pertitubular blood capillaries. Particle accumulation in peritubular blood capillaries was not sizedependent (Fig. S5) . Retention of particles in renal corpuscles, however, is a strong function of size (Fig. 3) . Smaller particles (Au 20 -PEG 5,000 NPs) entered the mesangium within renal corpuscles in minute quantities (Fig. 3A) . As size increases, Au x -PEG y NPs showed more association with mesangial cells. Au 50 -PEG 5,000 NPs accumulated in multiple clusters either within mesangial cells or in the extracellular matrix outside mesangial cells. The clustering density was the most pronounced among all particle sizes, consistent with the histological data (Fig. 3B) . Particles of similar sizes (Au 40 -PEG 4,000 and Au 60 -PEG 7,000 NPs) also showed appreciable particle accumulation in the mesangium (Fig.  S6) . Larger particles (Au 80 -PEG 10,000 NPs) only resided at the extracellular space in isolated amounts (Fig. 3C) . The TEM data reveal a size at which particle association with mesangial cells was maximal (Au 50 -PEG 5,000 NPs). This particular size maximized bulk kidney particle content and glomerular targeting. Thus, Au 50 -PEG 5,000 represents the particle size that maximizes kidney targeting at the organ, tissue, and cellular (mesangium) levels.
The average pore diameter of the fenestrated glomerular endothelia is reported to be 80-100 nm, roughly the hydrodynamic size of Au 50 -PEG 5,000 and Au 60 -PEG 7,000 NPs. Particles larger than this size cutoff (Au 80 -PEG 10,000 and Au 100 -PEG 20,000 NPs) may experience steric hindrance when permeating through the pores to enter the mesangium and access the mesangial cells. On the contrary, smaller particles (Au 20 -PEG 5,000 and Au 40 -PEG 4,000 NPs) are freely accessible to the mesangium. Thus, the size exclusion effect may account for the lower kidney particle content and weaker glomerular targeting of the largest particles. From TEM data, size-dependent uptake occurs solely at mesangial cells, which come in two types. The first type is contractile mesangial cells, which resemble vascular smooth muscle cells and fibroblasts that regulate surface area for glomerular filtration of fluids and mesangial volume. The second type involves mononuclear resident phagocytes derived from the bone marrow (17) . From the ICP-MS data, particle uptake by spleen macrophages and hepatic Kupffer cells (both of bone marrow origin) increases with increasing particle size. Below the size cutoff in kidney, larger particles (Au 50 -PEG 5,000 NPs) can penetrate through the endothelial pores, enter the mesangium, and accumulate inside mesangial cells (likely, the phagocytic-type mesangial cells). The smallest particles (Au 5 -PEG 5,000 NPs) may transiently enter the mesangium but may not favor prolonged retention because of lack of phagocytosis by mesangial cells. The absence of a cellular sink may lead to their low bulk particle content.
This work systematically examines the distribution of 10-to 150-nm nanoparticles in the kidney from a systemic injection. From measuring blood pharmacokinetics as well as distribution patterns at the organ, tissue, and cellular levels, the results suggest that there is an optimal size range (e.g., Au 50 -PEG 5,000 NPs) that maximizes bulk particle uptake in the kidney, deposition of particles in renal corpuscles within the cortex, and uptake of particles by mesangial cells within renal corpuscles. When using nanoparticles as cancer therapeutics, accumulations in single-digit percent ID amounts in the tumor can lead to gene inhibition and tumor reduction (18) . Thus, the accumulation of Au x -PEG y NPs (1-5% ID) in the kidney at these amounts may be able to impart efficacy with kidney diseases. Moreover, the lack of significant localization (0.7% ID) of larger particles (Au 80 -PEG 10,000 NPs; ∼130 nm in diameter) provides an in vivo calibration to the size of the glomerular endothelial pores. Most reported values for this pore size are derived from direct measurements of TEM and scanning electron microscopy (SEM) images. Sample processing for microscopy involves repeated dehydration and may lead to shrinkage of fine cellular features. The pore size reported here (130 nm) depicts the glomerular endothelial morphology at physiologically relevant conditions.
Materials and Methods
General. Unless otherwise mentioned, all PEG raw materials were purchased from Laysan Bio. All organic solvents were purchased from Sigma. PBS is comprised of 150 mM NaCl and 50 mM sodium phosphate (pH 7.4).
Synthesis of mPEG 4,000 -SH and mPEG 7,000 -SH. Fifty milligrams amine-PEG 3,400 -thiol (14.7 μmol) were reacted with 40.4 mg methoxy-PEG 550 -(succinimidyl propionate) (73.5 μmol) in 50 μL triethylamine (TEA) and 1.2 mL anhydrous dichloromethane (DCM). The reaction proceeded at room temperature (RT), with stirring for 7 h. The crude mixture was dried under vacuum and dialyzed against deionized water using a 3-kDa Amicon MWCO membrane (Millipore); 15 mg amine-PEG 5,000 -thiol (3.0 μmol) was reacted with 60 mg methoxy-PEG 2,000 -(succinimidyl valerate) (30.0 μmol) in 50 μL TEA and 1.2 mL anhydrous DCM. The reaction proceeded at RT, with stirring for 16 h. The crude mixture was dried under vacuum and dialyzed against deionized water using a 30-kDa Amicon MWCO membrane (Millipore). The correct fraction (7,000 Da) was separated with HPLC using a TSK gel G3000SW column (Tosoh Bioscience). Final molecular weights were confirmed by MALDI-TOF.
Assembly of Au x -PEG y NPs. Methoxy-PEG-thiol (purchased or synthesized above) of a particular molecular weight (y = 4,000, 5,000, 7,000, 10,000, and 20,000) and dissolved in deionized water was added to 3 mL aqueous suspension of unconjugated gold colloids (Ted Pella) of a designated core size (x = 5, 20, 40, 50, 60, 80, and 100 nm) at an excess concentration of ∼9 PEG strands per nm 2 gold surface [e.g., to ensure complete coverage, PEGylation of 50 nm AuNPs required the addition of 10 μL 1 mM mPEG 5,000 -thiol (in deionized water) to 0.5 mL aqueous suspension of 2.25 × 10
10 particles]. All PEGylation reactions proceeded at room temperature for 2 h with constant stirring. To remove any unbound methoxy-PEG-thiol, the reaction mixture was dialyzed against deionized water using a 30-or 100-kDa Amicon MWCO membrane (Millipore) three times.
Physicochemical Characterization of Au x -PEG y NPs. Hydrodynamic diameter (HD) and ζ-potential (ZP) of Au x -PEG y NPs were measured using ZetaPals (Brookhaven). For HD measurements, the particle pellet was resuspended in 1.2 mL deionized water or PBS. Reported HDs are average values from three runs of 3 min each. For ZP analysis, the pellet was resuspended in 1.4 mL 1 mM KCl. Reported ZPs are average values from 10 runs each, with a target residual of 0.012 measured at a conductance of 320 ± 32 μS.
Animal Experiments. For each type of Au x -PEG y NPs, three 9-wk-old female BALB/c mice (Jackson Laboratory) received i.v. injections of particles through the tail vein at a concentration of 4.5 × 10 11 particles/mL formulated in 120 μL filtered 5% glucose in deionized water (D5W). At three consecutive time points after injection (30 min, 4 h, and 24 h), 30 μL mouse blood were drawn from each mouse through its saphenous vein using Microvette CB 300 Capil-
